☆ 4.6 Article

Unresectable Ovarian Cancer Requires a Structured Plan of Action: A Prospective Cohort Study

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative)

Faiza Gaba et al.

Summary: The Global Gynecological Oncology Surgical Outcomes Collaborative (GO SOAR) has developed a network of professionals to collaborate on outcome studies. This article presents the protocol for the GO SOAR2 study, which aims to compare survival following different surgical treatments for ovarian cancer and assess international variations in access to cytoreductive surgery.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

Add to Collection

Review Oncology

Preoperative Cancer Antigen 125 Level as Predictor for Complete Cytoreduction in Ovarian Cancer: A Prospective Cohort Study and Systematic Review

Puck E. E. Brons et al.

Summary: This study evaluated the value of blood tumor marker CA-125 in predicting surgical outcomes for advanced stage ovarian cancer patients. The results showed that preoperative CA-125 levels <= 35 kU/L significantly predicted the outcome of interval cytoreductive surgery, but this parameter could not be used as an independent predictor.

CANCERS (2022)

Add to Collection

Article Oncology

Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands

G. M. Nieuwenhuyzen-de Boer et al.

Summary: The adjuvant use of PlasmaJet during surgery for advanced-stage ovarian cancer can significantly increase the proportion of complete cytoreduction in patients with resectable disease and improve quality of life.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Ovarian Cancer, Version 2.2020

Deborah K. Armstrong et al.

Summary: Epithelial ovarian cancer is a leading cause of gynecologic cancer death in the United States. The NCCN Guidelines discuss various ovarian cancers, focusing on primary treatment aspects and including recommendations for both common and rare subtypes.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer

Sebastjan Merlo et al.

Summary: Ovarian cancer is a common and deadly cancer in women. This study analyzed the experience of a comprehensive cancer center with preoperative CA-125 levels in ovarian cancer patients. Results showed that a preoperative CA-125 cutoff value of 500 IU/ml is promising to predict successful primary debulking surgery.

RADIOLOGY AND ONCOLOGY (2021)

Add to Collection

Review Oncology

Current Ovarian Cancer Maintenance Strategies and Promising New Developments

Vinaya Gogineni et al.

Summary: While ovarian cancer typically responds well to front line treatment, many patients will relapse within 5 years, highlighting the need for novel maintenance therapies. PARP inhibitors have gained approval in ovarian cancer maintenance, but their impact on overall survival is limited. This review focuses on current frontline ovarian cancer treatment and molecularly based approaches to ovarian cancer management.

JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)

Anna Fagotti et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

Add to Collection

Article Oncology

Does preoperative CA-125 cutoff value and percent reduction in CA-125 levels correlate with surgical and survival outcome after neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer? - Our experience from a tertiary cancer institute

Monisha Gupta et al.

SOUTH ASIAN JOURNAL OF CANCER (2020)

Add to Collection

Article Obstetrics & Gynecology

A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome

Beryl L. Manning-Geist et al.

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2019)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging in the pre-operative staging of ovarian cancer

Francesca Castellani et al.

ABDOMINAL RADIOLOGY (2019)

Add to Collection

Article Oncology

Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands

G. M. Nieuwenhuyzen-de Boer et al.

BMC CANCER (2019)

Add to Collection

Article Obstetrics & Gynecology

In patients with advanced ovarian cancer, primary suboptimal surgery has better survival outcome than interval suboptimal surgery

Alpaslan Kahan et al.

JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION (2019)

Add to Collection

Correction Oncology

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 24, pg 24, 2013)

J. A. Ledermann et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote et al.

LANCET ONCOLOGY (2018)

Add to Collection

Review Geriatrics & Gerontology

What is polypharmacy? A systematic review of definitions

Nashwa Masnoon et al.

BMC GERIATRICS (2017)

Add to Collection

Article Obstetrics & Gynecology

Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer

J. Borley et al.

BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer

Ignace Vergote et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article Oncology

Predictors of suboptimal surgical cytoreduction in women with advanced epithelial ovarian cancer treated with initial chemotherapy

A. E. Bland et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.